Abstract:Antipsychotic-induced weight gain (AIWG) contributes significantly to the 2-3-fold higher rates of obesity seen amongst those living with a severe mental illness (SMI). 1 Clinically significant weight gain (≥7% increase in weight) has been linked to almost all antipsychotics. 2 Adjunctive metformin treatment has been demonstrated to effectively reduce AIWG. 3 However, metformin's position within current AIWG management algorithms is typically limited to an option only to be considered after alternative interventions have been trialled and deemed unsuccessful. 4,5,6 One of the most recent guidelines influencing the management of AIWG in psychiatry is the 2018 World Health Organisation (WHO) guideline on the management of physical health conditions in adults with severe mental disorders. 4 Within this guideline, they recommend "where lifestyle interventions and/or switching psychotropic medication do not appear successful, adjunctive metformin may be considered. This should be considered under close clinical supervision and monitoring". 4 Leaving aside evidence addressing the comparative efficacy of pharmacological and non-pharmacological management interventions, whether such recommendations, and other similar guideline recommendations, 5,6 reflect the preferences of patients burdened with managing both a SMI and AIWG has recently been scrutinised within critiques of available management guidance. 7,8 Within this paper, we argue for much earlier and broader use of metformin to manage AIWG.Evidence demonstrating the efficacy of metformin primarily as an early intervention agent, rather than -as conventionally thought -a treatment of established AIWG will be outlined. We aim to demonstrate how inadequate consideration of the typical trajectory of weight gain following antipsychotic initiation among susceptible patients, and associated timing of metformin introduction within trials assessing its efficacy, have led to inaccurate conclusions regarding its role within management algorithms. Frequent barriers to the use of metformin cited by psychiatric clinicians include concern regarding it's risks and the appropriateness of prescribing glucose-lowering medications among cohorts without diabetes. 9,10 We will provide an overview of current risk estimates relating to established, but low risks of vitamin B12 deficiency and lactic acidosis. The rationale for why hypoglycaemia is not a concern when metformin is used in AIWG management will be discussed. Finally, the relationship between metformin and renal functioning and management strategies of common gastrointestinal side effects will also be discussed.Healthcare professionals can (often unconsciously) endorse stereotypical assumptions and stigmatising attitudes about those living with obesity. 7,11 Obesity management among those with a SMI may be particularly vulnerable to such implicit biases, where the experience of a 'dual stigma' has been described by those living with both obesity and a SMI. 12 Recommendations addressing weight management in this cohort may be uniquely susceptible to ideology and sociocultural values regarding the appropriateness of anti-obesity medications and expectations of self-management. 7 To date, recommendations addressing weight management within SMI cohorts have largely been informed by the expert opinion of guideline development groups -with no or minimal patient input. 4,5,6 Until recently, 7 availability of empirical evidence outlining patient values and preferences for management interventions, including their acceptability and transferability across cohorts and contexts, was relatively unexplored. The prognosis of AIWG is highly variable. 13,14 Thus, patient management preferences are likely also extensively variable. We believe the absence of this diverse lived experience representation within guideline development groups limits the applicability and clinical utility of current guideline recommendations, where the role of metformin remains inappropriately limited.The largest proportion of total weight gained occurs within the first 12 months of antipsychotic treatment. 13 Whilst AIWG can continue after this time, this is typically at a much slower rate. 13,15,16 In this way, the relationship between duration of antipsychotic treatment and weight gain can be described as hyperbolic (weight increases steadily early in treatment until a plateau is approached). This has been demonstrated with antipsychotics associated with medium-and/or high-risk of inducing clinically significant AIWG and is largely independent of dose. 17,18 Current understanding of mechanisms behind this hyperbolic relationship and eventual reaching of AIWG plateau suggests that antipsychotics interfere with homeostatic mechanisms regulating weight and total body fat mass, culminating in the development of a new body weight set-point. 19 Mechanisms responsible for the orexigenic effects of antipsychotics are t -Abstract Truncated-

Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study

Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study

CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine

CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine

Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis

Effect of Combined Treatment with Clozapine and Metformin on Fasting Blood Glucose, Insulin Level, and Expression of the Glucose Transporter-2 (GLUT2) in Sprague-Dawley Rats.

The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression

Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain

Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: a Double-Blind, Placebo-Controlled Study.

Metformin for Treatment of Antipsychotic-Induced Amenorrhea and Weight Gain in Women with First-Episode Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Study

Metformin for olanzapine-induced weight gain in schizophrenia:a systematic review

Metformin in the management of antipsychotic-induced weight gain – why the 'weight'?

Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials.

M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY

Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: a Randomized Controlled Trial.

Metformin Treatment of Antipsychotic-Induced Dyslipidemia: an Analysis of Two Randomized, Placebo-Controlled Trials.

Effects of Clozapine Administration on Body Weight, Glucose Tolerance, Blood Glucose Concentrations, Plasma Lipids, and Insulin in Male C57BL/6 Mice: A Parallel Controlled Study.

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial

Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials.

Birth weight, leptin and adiponectin in patients initiating clozapine

Metformin addition therapy attenuates olanzapine-induced weight gain